Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

3151 - 3160 of 3632 results found

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

MeSH Terms
Carcinoma; Hepatocellular (C04.588.274.623.160) Neoplasms (C04)
  • Neoplasms by Site (C04.588)
    • Digestive System Neoplasms (C04.588.274)
      • Liver Neoplasms (C04.588.274.623)
        • Carcinoma, Hepatocellular (C04.588.274.623.160)
Guideline Contact
[email protected]
Date for Review
22-Nov
Publication Date
16-Nov-20
Date of Last Evidence Search
15-May-20
Publication Scope
treatment
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ASCO (US)
Publication Year
2020

Systemic therapy for advanced or recurrent endometrial cancer, and advanced or recurrent uterine papillary serous carcinoma

MeSH Terms

Endometrial Neoplasms (C04.588.945.418.948.585); Uterine Neoplasms (C04.588.945.418.948); Drug Therapy (E02.319); Drug Therapy; Combination (E02.319.310); Antineoplastic Agents (D27.505.954.248)

Guideline Contact
Cindy Walker-Dilks ([email protected])
Publication Scope
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
McMaster University (CA)
Publication Year
2017

Systemic Therapy for Metastatic Urothelial Cancer: An Endorsement of a Portion of the European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer

Guideline Contact
Judy Brown; [email protected]
Date for Review
In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
Publication Date
09/08/2022
Publication Scope
Guidelines
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Publication Year
2022

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update

MeSH Terms
Neoplasms (C04); Breast Neoplasms (C04.588.180); Pharmacologic Actions (D27.505)
Guideline Contact
[email protected]
Publication Date
25-Jun-18
Publication Scope
prognosis
treatment
Countries of Application
United States
Guideline Publication Status
Under Review
Languages
English
Authors
ASCO (US)
Publication Year
2018

Systemic therapy for the treatment of adult patients with lower-risk myelodysplastic syndromes

MeSH Terms

Consensus Development Conference (V03.300); Consensus (F01.829.316.068); Myelodysplastic Syndromes (C15.378.190.625)

Guideline Contact
Cindy Walker-Dilks ([email protected])
Publication Scope
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
McMaster University (CA)
Publication Year
2018

Systemic therapy for unresectable advanced or metastatic pancreatic and midgut neuroendocrine tumours: Version 2

MeSH Terms

Neuroendocrine Carcinoma, Gastroenteropancreatic neuroendocrine tumor, Phase 3 Clinical Trial, Phase 4 Clinical Trial, Randomized Controlled Trial, Guideline, Systematic Review, Quality Assessment, Adult, Octreotide, 177Lu-Dotatate, 90y-Dotatate

Guideline Contact
Roxanne Cosby; [email protected]
Keywords
Guideline, Midgut Neuroendocrine Tumours, Pancreatic Neuroendocrine Tumours, Systemic Therapy, Systematic Review
Date for Review
The Program in Evidence-based Care (PEBC), Ontario Health (CCO) has an annual review process for each guideline. Guidelines are reviewed every fall, one year after they are completed
Publication Date
March 2024
Date of Last Evidence Search
October 30, 2023
Methods Applied
Evidence-based; Systematic review-based; External review; Evidence quality assessment; Patient/survivor/caregiver participation
Publication Scope
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
PEBC (Program in evidenced-based care)
Publication Year
2024